Business Description
Agios Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US00847X1046
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 16.52 | |||||
Equity-to-Asset | 0.91 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.15 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 8.67 | |||||
Beneish M-Score | -1.19 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -13.5 | |||||
3-Year EPS without NRI Growth Rate | -9.9 | |||||
3-Year FCF Growth Rate | -8.6 | |||||
3-Year Book Growth Rate | 36 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 98.47 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 23.4 | |||||
9-Day RSI | 28.63 | |||||
14-Day RSI | 30.86 | |||||
3-1 Month Momentum % | 1.01 | |||||
6-1 Month Momentum % | -7.37 | |||||
12-1 Month Momentum % | 102.01 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 8.99 | |||||
Quick Ratio | 8.77 | |||||
Cash Ratio | 8.41 | |||||
Days Inventory | 2295.73 | |||||
Days Sales Outstanding | 31.8 | |||||
Days Payable | 1283.6 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 6.9 | |||||
Shareholder Yield % | 0.77 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 89.38 | |||||
Operating Margin % | -1238.1 | |||||
Net Margin % | 2051.38 | |||||
FCF Margin % | -1004.2 | |||||
ROE % | 71.3 | |||||
ROA % | 62.91 | |||||
ROIC % | -116.85 | |||||
3-Year ROIIC % | 39.42 | |||||
ROC (Joel Greenblatt) % | -521.13 | |||||
ROCE % | -40.71 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 2.85 | |||||
Price-to-Owner-Earnings | 2.99 | |||||
PS Ratio | 56.19 | |||||
PB Ratio | 1.14 | |||||
Price-to-Tangible-Book | 1.14 | |||||
EV-to-EBIT | -2.22 | |||||
EV-to-Forward-EBIT | -0.81 | |||||
EV-to-EBITDA | -2.26 | |||||
EV-to-Revenue | 27.53 | |||||
EV-to-Forward-Revenue | 8.98 | |||||
EV-to-FCF | -2.74 | |||||
Price-to-Net-Current-Asset-Value | 2.03 | |||||
Price-to-Net-Cash | 2.2 | |||||
Earnings Yield (Greenblatt) % | -45.05 | |||||
FCF Yield % | -17.85 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Agios Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 30.127 | ||
EPS (TTM) (€) | 10.133 | ||
Beta | 1.16 | ||
3-Year Sharpe Ratio | 0.28 | ||
3-Year Sortino Ratio | 0.45 | ||
Volatility % | 77.97 | ||
14-Day RSI | 30.86 | ||
14-Day ATR (€) | 1.0793 | ||
20-Day SMA (€) | 32.87 | ||
12-1 Month Momentum % | 102.01 | ||
52-Week Range (€) | 19.4 - 58 | ||
Shares Outstanding (Mil) | 57.03 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Agios Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Agios Pharmaceuticals Inc Stock Events
Event | Date | Price (€) | ||
---|---|---|---|---|
No Event Data |
Agios Pharmaceuticals Inc Frequently Asked Questions
What is Agios Pharmaceuticals Inc(FRA:8AP)'s stock price today?
When is next earnings date of Agios Pharmaceuticals Inc(FRA:8AP)?
Does Agios Pharmaceuticals Inc(FRA:8AP) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |